BACKGROUND: Few previous studies investigating depression before the diagnosis of breast cancer and breast cancer-specific mortality have examined depression measured at more than 1 time point. This study investigated the effect of depression (combining depressive symptoms alone with antidepressant use) measured at 2 time points before the diagnosis of breast cancer on all-cause mortality and breast cancer-specific mortality among older postmenopausal women. METHODS: A large prospective cohort, the Women's Health Initiative, was used. The study included 3095 women with incident breast cancer who had measures of depressive symptoms and antidepressant use before their diagnosis at the baseline and at year 3. Multivariate Cox proportional hazards regression was used to estimate adjusted hazard ratios (HRs) between depression at the baseline, depression at year 3, and combinations of depression at these time points and all-cause mortality and breast cancer-specific mortality. RESULTS: Depression at year 3 before a breast cancer diagnosis was associated with higher all-cause mortality after adjustments for multiple covariates (HR, 1.35; 95% confidence interval [CI], 1.02-1.78). There was no statistically significant association of baseline depression and all-cause mortality or breast cancer-specific mortality whether or not depression was also present at year 3. In women with late-stage (regional-or distantstage) breast cancer, newly developed depression at year 3 was significantly associated with both all-cause mortality (HR, 2.00; 95% CI, 1.13-3.56) and breast cancer-specific mortality (HR, 2.42; 95% CI, 1.24-4.70). CONCLUSIONS: Women with newly developed depression before the diagnosis of breast cancer had a modestly but significantly increased risk for death from any cause and for death from breast cancer at a late stage. Cancer 2017;123:3107-15.
INTRODUCTION
Breast cancer is one of the most common cancers and represents 14.6% of new cancer cases in the United States.
1 The cancer stage, comorbid conditions, age, and socioeconomic status are well-known prognostic factors for breast cancer-specific mortality. 2 The effect of depression before the diagnosis of breast cancer on all-cause mortality has been an area of interest in several studies from different countries. [3] [4] [5] In a national cohort study in Denmark, Hjerl et al 4 indicated that depression before the diagnosis of breast cancer was associated with significantly higher mortality among women with breast cancer (hazard ratio [HR], 1.30; 95% confidence interval [CI], 1.13-1.49). Similarly, among women with breast cancer aged 67 to 90 years in the United States, a prior diagnosis of depression in the 2 years before the diagnosis of breast cancer was associated with significantly higher all-cause mortality (HR, 1.42; 95% CI, 1.13-1.79). 5 In a recently published study from the United Kingdom, patients with a record of depression before the diagnosis of breast cancer had a higher mortality rate than women without depression (HR, 1.23; 95% CI, 1.07-1.42). 3 Previous studies measured depression or depressive symptoms before the breast cancer diagnosis only at 1 time point, that is, the baseline. Other studies followed women with depression after their breast cancer diagnosis over time and showed a decreasing strength of association between depression and all-cause mortality with a longer follow-up time. For example, in a cohort study in the United Kingdom, breast cancer survivors with depressive symptoms had a higher risk of death over a 5-year follow-up, 6 but this association became nonsignificant at the 10-year follow-up. 7 The single rating of depressive symptoms at the baseline loses predictive validity over time. 8 However, no prospective observational study with at least 2 repeated measurements of depressive symptoms and long follow-up has been performed to examine the relation between persistent depression and all-cause death or breast cancer-specific death. A study with this design could also determine whether the proximity of depression to the breast cancer diagnosis influences the prognosis of breast cancer patients.
The Women's Health Initiative (WHI) is a large prospective cohort study with extensive data on comorbid conditions and risk factors and a long follow-up. Thus, we took advantage of the rich WHI data and used the depressive symptom data at the baseline and the 3-year follow-up point. We assessed the effects of depressive symptoms and antidepressant treatment measured at these 2 time points on all-cause and breast cancer-specific mortality in women who developed breast cancer after the year 3 follow-up.
MATERIALS AND METHODS

Data Source
The WHI program was launched in 1993, and postmenopausal women aged 50 to 79 years (n 5 161,808) were recruited from 40 US nationwide clinical centers into either 3 clinical trials or an observational study. 9 Written informed consent and Institutional Review Board approval were acquired by each participating WHI site.
Participants
Because the diagnosis of breast cancer could affect depressive symptoms, we included only observational-study women newly diagnosed with invasive breast cancer after the year 3 visit (Fig. 1) . The mean length of time was 8.7 years (range, 3-17.9 years) from the baseline to the breast cancer diagnosis, 5.7 years (range, 0-14.9 years) from year 3 to the breast cancer diagnosis, and 6.8 years (range, 0-15.2 years) from the breast cancer diagnosis to the end of follow-up. Incident invasive breast cancers were initially ascertained on the basis of the participants' self-reporting, were adjudicated by physicians using medical records and pathology reports, and were then coded according to Surveillance, Epidemiology, and End Results Program criteria by the WHI Clinical Coordinating Center. 10 Women with a history of cancers other than nonmelanoma skin cancers at the baseline were excluded. There were 4482 women with incident breast cancer in the observational study through September 20, 2013. Women who had missing information on depressive symptoms at either the baseline (n 5 85) or year 3 (n 5 367) or whose follow-up period was less than 3 years (n 5 11) were excluded. Women with breast cancer diagnosed between the baseline and the year 3 visit were also excluded (n 5 924). The final sample used for this analysis included 3095 women (Fig. 1 ).
Exposures
The main exposures included depressive symptoms and antidepressant use at the baseline interview and the third year follow-up. All women enrolled in the observational study were asked to complete a questionnaire on depressive symptoms at the baseline and the 3-year visit. The depression scores were computed from a short (6-item) form of the Center for Epidemiologic Studies Depression Scale plus 2 questions from the National Institute of Mental Health's Diagnostic Interview Schedule. This self-report measure departed from traditional depressive symptom screeners because individual items were differentially weighted and included the diagnostically relevant duration of depressed mood. 11 The depression score ranged from 0 to 1. A higher score indicates a greater likelihood of depression. We categorized depressive symptoms as no or yes on the basis of a cut point of 0.06, 11 which has been established to have high sensitivity and a good positive predictive value for screening depressive disorders. 
Use of antidepressants
Treatment for depression was determined from medications brought by the participants in their original pill bottles for all medications to the baseline visit and the year 3 follow-up visit. Drug information was entered into a medication database derived from the Master Drug Database (Medi-Span, Indianapolis, Ind). The National Drug Code for Antidepressant Medications Management was used to categorize whether a drug was an antidepressant or not. 12 In the analysis, trazodone was not considered an antidepressant because of its common use as a sedative or hypnotic. 13 Participants were categorized as antidepressant users or nonusers at either time point.
Definition of depression
Because depressive symptoms and antidepressant use were closely linked, a jointly defined variable was considered in this study, and it was called depression. The definition of depression in this study combined these 2 variables: women with either depressive symptoms or antidepressant use were classified as depressed, and those with neither factor were classified as nondepressed.
The combinations of depression at 2 time points were classified as follows: "no at both time points" if there was no depression at the baseline or at the third year follow-up, "baseline only" if there was depression at the baseline but there was no depression at the third year follow-up, "year 3 only" if there was no depression at the baseline but there was depression at the third year followup, and "yes at both time points" if there was depression at both time points.
Outcomes
The primary outcomes of interest were all-cause mortality and breast cancer-specific mortality. The WHI data was linked with the National Death Index of the National Center for Health Statistics. All causes of death were centrally adjudicated by physicians using available medical records, death certificates, and informant interviews. 10 Incident invasive breast cancer was coded for the diagnosis date, stage, grade, and estrogen and progesterone receptors, and it was ascertained and adjudicated. The end of the follow-up time was based on the last period covered by National Death Index review.
Covariates
Race/ethnicity was categorized as white (not of Hispanic origin) or other. The body mass index was calculated as the weight (kg) divided by the height (m 2 ). The smoking status included never smokers, former smokers, and current smokers (with never smokers as the reference). A history of postmenopausal hormone therapy (the treatment of postmenopausal women with estrogen alone or estrogen plus progestin) was categorized as ever use or never. A comorbidity index was measured through the combination of 10 co-occurring self-reported conditions at the baseline, including glaucoma, high cholesterol levels requiring pills, asthma, emphysema or chronic bronchitis, a stomach or duodenal ulcer, osteoporosis (weak, thin, or brittle bones), cardiovascular disease, arthritis, a thyroid gland problem other than thyroid cancer, and hypertension. Comorbidities were categorized as 0 (no comorbidity beyond breast cancer), 1 (1 comorbid condition), 2 (2 comorbid conditions), or 3 (3 or more comorbid conditions). Mammography use during the last 2 years was categorized as yes or no. Breast tumors were characterized according to their stage (with the localized stage as the reference; regional and distant stages were grouped together as "late stage," and the localized stage was classified as "early stage";), grade (with low grade as the reference), estrogen receptor status (positive vs not positive), and progesterone receptor status (positive vs not positive). There was treatment information only for women aged 65 years or older. Surgery was classified as no, mastectomy, or lumpectomy/breast-conserving; chemotherapy was classified as yes or no; and radiation was also classified as yes or no.
Statistical Analysis
Participants' characteristics and tumor information were compared between women with and without depression at the baseline and at 2 time points. Means and standard deviations were used to describe continuous characteristics at the baseline, whereas proportions were used for categorical variables. A t test and an analysis of variance were used for continuous variables, and a chi-square test was used to analyze categorical variables.
All-cause mortality and breast cancer-specific mortality stratified by depression were estimated with the Kaplan-Meier method first. Multivariate Cox proportional hazards regression was used to estimate adjusted HRs for each outcome (all-cause mortality and breast cancerspecific mortality). We analyzed depression at the baseline and at the year 3 visit and combinations of depression at the 2 time points. In the Cox models, potential confounders included the following: age; race; body mass index; smoking; history of postmenopausal hormone therapy; comorbidity at the baseline; and tumor stage, tumor grade, and estrogen receptor and progesterone receptor status at the date of the breast cancer diagnosis.
The survival time was measured as the time from the breast cancer diagnosis to death or the end of follow-up, whichever came first. For all-cause mortality analyses, persons alive at the end of follow-up were treated as censored observations. For breast cancer-specific mortality, we classified cancer-specific deaths with an underlying cause of death, and persons who were alive at the end of followup or who died of noncancer causes were treated as censored observations.
We evaluated the effect modification by stage (localized vs regional and distant), grade (low, intermediate, or high), estrogen receptor status (positive vs not positive), and progesterone receptor status (positive vs not positive).
We performed 4 sensitivity analyses to assess the robustness of our findings. First, because the proximity of depression may be important, we added the duration from year 3 to the breast cancer diagnosis to the analysis models. Second, we replaced the variable combining depressive symptoms and antidepressant use with a variable based on depressive symptoms alone in the models. Third, we included only incident breast cancer diagnosed after year 4 to account for depression related to as yet undiagnosed breast cancer. Fourth, we performed a sensitivity analysis by making further adjustments for treatment information among women aged 65 years or older.
RESULTS
Among the 3095 women, the prevalence of depression at the baseline was 11.5% (n 5 357; Table 1 ). The proportions of women with depressive symptoms alone and antidepressant use at the baseline were 9.4% (n 5 290) and 2.8% (n 5 87), respectively. The prevalence of depression at year 3 was 12.5% (n 5 386). The proportions of women with depressive symptoms alone and antidepressant use at year 3 were 8.8% (n 5 272) and 4.8% (n 5 149), respectively. Compared with women without depression at the baseline, women with depression were more likely to be younger, have a higher body mass index, be physically inactive, be current smokers, have a history of postmenopausal hormone therapy, and have more comorbid conditions (all P values < .05). Alcohol intake, mammography history, and tumor characteristics did not differ between women with and without depression at the baseline, but alcohol intake and mammography history differed between women with and without depression at the 2 time points.
Among women with invasive breast cancer, there was no association between baseline depression and allcause mortality (Table 2) . However, the association of year 3 depression and subsequent all-cause mortality remained significant in 4 models adjusted for different covariates (HR, 1.35-1.49; all P values < .05). Although point estimates of the HR for breast cancer-specific mortality were similar to those for overall mortality, there were few cases and wide CIs, so there was not a significant association of depression at the year 3 visit with breast cancer-specific mortality in the models after adjustments for age or multiple covariates (Table 2) .
We next examined combinations of baseline and year 3 depression (Table 3 ). Neither newly developed depression (present at year 3 but not at the baseline) nor persistent depression (present at the baseline and year 3) was associated with all-cause mortality after adjustments for multiple covariates. The point estimates for breast cancer-specific mortality were similar to those for all-cause mortality but were statistically weaker because of larger CIs.
Effect modification analysis by tumor characteristics showed that women with late-stage cancer and with newly developed depression had the greatest all-cause mortality risk (HR, 2.00; 95% CI, 1.13-3.56; Table 4 ). A similar effect was found on breast cancer-specific mortality (HR, 2.42; 95% CI, 1.24-4.70).
The results of the sensitivity analyses were generally similar to the main findings when the follow-up duration from year 3 to the breast cancer diagnosis was added to the analysis models, when the variable combining depressive symptoms and antidepressant use was replaced by a variable based on depressive symptoms alone in the models, and when only incident breast cancer diagnosed after year 4 was included. In the sensitivity analysis with further adjustments for treatment information for women aged 65 years or older, we observed HRs of magnitudes similar to the main results, but because of the reduced sample size (half of the women had treatment information), none of them reached statistical significance.
DISCUSSION
This is the first prospective, observational study to explore the effect of depression at 2 time points before the breast cancer diagnosis on all-cause mortality and breast cancerspecific mortality. The results indicate that newly developed depression (present at year 3 but not at the baseline) before the breast cancer diagnosis was associated with higher all-cause mortality and breast cancer-specific mortality among late-stage breast cancer survivors.
With the WHI data, Brown et al 14 found that neither depression nor antidepressant use was associated with increased breast cancer risk, but no WHI study has been performed to explore the effect of depression on breast Original Article cancer mortality. Several other studies have demonstrated that for breast cancer survivors, a prior diagnosis of depression is associated with higher mortality, [3] [4] [5] and this is consistent with our study findings. Few studies have evaluated whether depression at 2 or more time points before the breast cancer diagnosis is associated with the risk for death from all causes or breast cancer; exceptions include several randomized trials for breast cancer survivors, which have demonstrated that improvements in depressive symptoms after psychiatric group interventions (eg, enhancement of coping skills and psychological support) increase survival. 15, 16 However, in this study, neither depression at the baseline only nor depression at both the baseline and year 3 was associated with increased all-cause mortality.
Hjerl et al 4 indicated that depression before the breast cancer diagnosis was associated with significantly increased mortality for late-stage breast cancer survivors but not for early-stage breast cancer survivors, and this is also similar to our findings. The current study showed that among women with subsequent late-stage breast cancer, newly developed depression at year 3 was associated 
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Cancer August 15, 2017 with the risk of both all-cause mortality and breast cancer-specific mortality. Possible explanations for the particular association of newly developed but not persistent depression may be explained by the difficulty in dealing with new depression in comparison with having coped with depression for longer times. This new depression may develop from changes in life circumstances, other unmeasured illness, or stress, which may have physiological impacts on other disease mechanisms, or lead to different screening behaviors. Although mechanisms between depression and breast cancer survival are not very clear, discussions of causal links usually include 2 broad categories of explanation. The first category sees depression as an indication of global brain dysfunction. 5 Depression influences the neuroendocrine axis, neuroimmunological function, and other central nervous system activities. This central nervous system dysregulation puts the organism at greater risk for morbidity and mortality. 17 The second category indicates that depression renders breast cancer survivors less capable of functioning successfully in modern society. 16 People with depression are less likely to receive appropriate and correct health screening, although our results do not indicate any differences in breast cancer screening between women with and without depression at the baseline. Some studies suggest that cancer survivors may be faced with difficulties in adhering to chemotherapy and other complementary treatment, 17 and this can lead to faster cancer progression. Therefore, depressive symptoms may impair the effect of conventional medical treatment, 17 although our results from the sensitivity analysis do not show the difference in treatment between women aged 65 years or older with and without depression at the baseline. This study's unique contributions include using a large prospective cohort to explore the effect of depression at 2 time points on all-cause mortality and breast cancerspecific mortality. Our study has limitations. First, as time-dependent variables, depressive symptoms and antidepressant use were surveyed only at the baseline and year 3. However, the WHI provided a relatively long time interval between the measurement of depression and the assessment of mortality. Second, there is treatment information for incident breast cancer in the WHI data only for women aged 65 years or older. This article does not include information about endocrine therapy. However, it appears that differences in mortality rates are not entirely explained by treatment disparities, and as such, depression leading to mortality differences may not be entirely due to difficulty with compliance. The third limitation is that depressive symptoms, assessed via a self-report scale as we had in the WHI, are not equivalent to a clinical diagnosis of depression. However, among WHI participants, the depression-screening method was found to have a sensitivity of 74% and a specificity of 87% in comparison with a clinician's diagnosis of depression. 18 In addition, women were unlikely to have depressive symptoms if they had depression but were effectively treated. Therefore, antidepressant use was combined into the definition of depressive symptoms, and this improved the identification of depressed women. Fourth, the association between depression and mortality is very much driven by the quality of symptoms: their severity, chronicity, and even type. 19 In the WHI, there was no exclusion for women with depression, but severely depressed women probably were less likely to volunteer for the study. Thus, there was a fairly restricted range of depression scores, which could limit, to some extent, generalization of the results. Lastly, white women accounted for 90% of the participants in the current study, and this could also limit generalization to more diverse populations.
Further studies should explore breast cancer-specific mortality associated with depression with multiple measurements during follow-up, which could capture a longterm trend in depression. In addition, further studies should assess the effects of the interactions of depressive symptoms, antidepressant use, and breast cancer treatment on the risk of death from breast cancer, with special consideration given to detailed, specific medication data.
In conclusion, women with newly developed depression before the diagnosis of breast cancer had a modestly but significantly increased risk for death from any cause and for death from breast cancer if they were diagnosed at a late stage. The results also highlight the importance of prevention efforts for supporting mental health and preventing the initial emergence of depression among older women.
FUNDING SUPPORT
The research reported in this publication was supported by the National Cancer Institute (National Institutes of Health) under award R15CA179463; the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study was also supported by a grant from the Youth Scholars Program of Beijing Normal University. The Women's Health Initiative is funded by the National Heart, Lung, and Blood Institute (National Institutes of Health, US Department of Health and Human Services) through 
